UNITED KINGDOM: Cannabis smoke exposure, even long-term, is not positively associated with chronic obstructive pulmonary disease (COPD), lung cancer, or irreversible airway damage, according to a literature review published in the journal Breathe.
ISRAEL: The daily administration of low doses of oral THC is associated with treating various symptoms associated with anorexia nervosa, according to clinical trial data published in The Israeli Journal of Psychiatry and Related Sciences.
Investigators with Hebrew University in Jerusalem and the Eating Disorders Institution at the University of Haifa assessed the daily use of up to 2mgs of oral THC in patients suffering from chronic anorexia. Participants in the open-label trial ingested THC for a period of three weeks.
Researchers reported significant improvements in participants’ self-reported body care, depression, and asceticism (avoidance of all forms of indulgence). Authors further reported that all but two of the nine patient participants gained weight over the course of the trial.
“The present study is the first to show improvement in the psychological symptoms of patient with AN (anorexia nervosa) when treated with delta-9-THC, without side effects,” authors concluded. “These encouraging results on a group of chronic AN patients suggest that low doses of delta-9-THC should be further studied as an adjunct to the treatment of patients with AN.”
For more information, contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “The impact of delta-9-THC on the psychological symptoms of anorexia nervosa: A pilot study,” appears in The Israeli Journal of Psychiatry and Related Sciences.
ISRAEL: The adjunctive use of high CBD oral extracts is associated with improvements in symptom management in children with autism-related behavioral issues, according to clinical data published online ahead of print in the journal Neurology.
Israeli researchers assessed the use of oral extracts containing a 20 to 1 ratio of CBD to THC in 60 adolescents with autism spectrum disorder.
Following treatment, behavioral outbreaks were “much improved or very much improved in 61 percent of patients.” Nearly half of all patients reported improvement in anxiety and in their communication skills, while 29 percent reported a decrease in disruptive behaviors.
Authors concluded, “This preliminary study supports the feasibility of CBD-based medical cannabis as a promising treatment option for refractory behavioral problems in children with ASD.”
For more information, contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the study, “Cannabis-based medical cannabis in children with autism – A retrospective feasibility study,” appears in Neurology.